Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in the Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

SUBMITTED IND APPLICATION IN THE U.S. FOR DENOSUMAB INJECTION (LY06006/LY01011)

The board of directors (the "Board") of Luye Pharma Group Ltd. (the "Company", together with its subsidiaries "Group") is pleased to announce that Shandong Boan Biological Technology Co. Ltd. 山東博安生物技術有限公司 ("Shandong Boan", a subsidiary of the Group) has recently submitted the investigational new drug ("IND") application for its recombinant anti-RANKL fully human monoclonal antibody injection (Denosumab Injection, LY06006/LY01011) product to the Food and Drug Administration of the United States of America (the "U.S"). It is the first overseas IND application regarding a biopharmaceutical product of the Group.

Denosumab injection at dose of 60mg/ml ("LY06006") is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture, treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer and treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Denosumab injection at the dose of 120 mg/1.7ml ("LY01011") is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

LY06006 and LY01011 are biosimilars to Prolia and Xgeva, and are currently in phase III and phase I clinical trials in China, respectively.

According to public financial reports, sales of Prolia (the reference drug for LY06006) amounted to US$2.67 billion in 2019 globally with annual growth of 16.6%, Prolia has not been launched in China yet. The sales of Xgeva (the reference drug for LY01011) amounted to US$1.94 billion in 2019 globally with an annual growth of 8.3%. Xgeva was launched in China in May 2019.

In addition to LY06006/LY01011, the Group has five more biosimilar products at different stages of development, including LY01008 (biosimilar to Avastin), LY09004 (biosimilar to Eylea), LY01012 (biosimilar to Zaltrap), LY01015 (biosimilar to Opdivo), LY05008 (biosimilar to Trulicity), The marketing authorization application for LY01008 (Bevacizumab injection, biosimilar to Avastin) has been accepted by the China Center for Drug Evaluation of National Medical Products Administration of China.

The Group will continue to invest in research and development of biopharmaceuticals, to accelerate the deployment of the Group's innovative bio-pharmaceuticals, and to further expand the Group's product pipeline.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 8 May 2020

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive director of the Company is Mr. SONG Rui Lin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.